A Study Exploring the PK/PD Relationship of QRL-101 in Adults With ALS
Phase 1
Recruiting
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: QRL-101Other: Placebo
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- QurAlis Corporation
- Target Recruit Count
- 12
- Registration Number
- NCT06714396
- Locations
- 🇳🇱
Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
A 3-way Cross-over Study on the Effects of QRL-101 on Transcranial Magnetic Stimulation and Nerve Excitability in Healthy Participants
Phase 1
Recruiting
- Conditions
- Healthy
- Interventions
- Drug: QRL-101 Dose ADrug: QRL-101 Dose BDrug: Placebo
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- QurAlis Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT06681441
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
A Study Evaluating Multiple Ascending Doses of QRL-101 in Healthy Participants
Phase 1
Recruiting
- Conditions
- Healthy Volunteers
- Interventions
- Drug: PlaceboDrug: QRL-101
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- QurAlis Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT06532396
- Locations
- 🇳🇱
ICON plc. Van Swietenlaan 6, Groningen, Netherlands
A Study Evaluating Safety, Tolerability, and Pharmacokinetics of QRL-101 in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: QRL-101Other: Placebo
- First Posted Date
- 2022-12-29
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- QurAlis Corporation
- Target Recruit Count
- 88
- Registration Number
- NCT05667779
- Locations
- 🇳🇱
ICON plc. Van Swietenlaan 6, Groningen, Netherlands
A Study Evaluating the Safety and Tolerability of QRL-201 in ALS
Phase 1
Recruiting
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: Multiple ascending doses of QRL-201Drug: PlaceboDrug: Multiple ascending doses of PlaceboDrug: QRL-201
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- QurAlis Corporation
- Target Recruit Count
- 64
- Registration Number
- NCT05633459
- Locations
- 🇬🇧
Kings College Hospital NHS Foundation Trust, London, United Kingdom
🇧🇪Universitaire Ziekenhuizen Leuven (UZ Leuven), Leuven, Belgium
🇨🇦University of Calgary, Calgary, Alberta, Canada
© Copyright 2025. All Rights Reserved by MedPath